<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gemmel, M.</style></author><author><style face="normal" font="default" size="100%">Rayen, I.</style></author><author><style face="normal" font="default" size="100%">van Donkelaar, E.</style></author><author><style face="normal" font="default" size="100%">Loftus, T.</style></author><author><style face="normal" font="default" size="100%">Steinbusch, H. W.</style></author><author><style face="normal" font="default" size="100%">Kokras, N</style></author><author><style face="normal" font="default" size="100%">Dalla, C</style></author><author><style face="normal" font="default" size="100%">Pawluski, J. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Gestational stress and fluoxetine treatment differentially affect plasticity, methylation and serotonin levels in the PFC and hippocampus of rat dams</style></title><secondary-title><style face="normal" font="default" size="100%">Neuroscience</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">antidepressant medication</style></keyword><keyword><style  face="normal" font="default" size="100%">Antidepressive Agents/pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Brain/*drug effects/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Depression/drug therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Depressive Disorder/drug therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Fluoxetine/*pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Hippocampus/*drug effects/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Methylation</style></keyword><keyword><style  face="normal" font="default" size="100%">Neuronal Plasticity/*drug effects</style></keyword><keyword><style  face="normal" font="default" size="100%">Neuroplasticity</style></keyword><keyword><style  face="normal" font="default" size="100%">neurotransmitters</style></keyword><keyword><style  face="normal" font="default" size="100%">Postpartum depression</style></keyword><keyword><style  face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style  face="normal" font="default" size="100%">Prenatal Exposure Delayed Effects/*drug therapy/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Rats, Sprague-Dawley</style></keyword><keyword><style  face="normal" font="default" size="100%">Selective Serotonin Reuptake Inhibitors/*pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Serotonin/*metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Ssri</style></keyword><keyword><style  face="normal" font="default" size="100%">Stress, Physiological</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jul 7</style></date></pub-dates></dates><edition><style face="normal" font="default" size="100%">20160411</style></edition><volume><style face="normal" font="default" size="100%">327</style></volume><pages><style face="normal" font="default" size="100%">32-43</style></pages><isbn><style face="normal" font="default" size="100%">0306-4522</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Women are more likely to develop depression during childbearing years with up to 20% of women suffering from depression during pregnancy and in the postpartum period. Increased prevalence of depression during the perinatal period has resulted in frequent selective serotonin reuptake inhibitor (SSRI) antidepressant treatment; however the effects of such medications on the maternal brain remain limited. Therefore, the aim of the present study is to investigate the effects of the SSRI medication, fluoxetine, on neurobiological differences in the maternal brain. To model aspects of maternal depression, gestational stress was used. Sprague-Dawley rat dams were exposed to either gestational stress and/or fluoxetine (5mg/kg/day) to form the following four groups: 1. Control+Vehicle, 2. Stress+Vehicle, 3. Control+Fluoxetine, and 4. Stress+Fluoxetine. At weaning maternal brains were collected. Main findings show that gestational stress alone increased synaptophysin and serotonin metabolism in the cingulate cortex2 region of the cortex while fluoxetine treatment after stress normalized these effects. In the hippocampus, fluoxetine treatment, regardless of gestational stress exposure, decreased both global measures of methylation in the dentate gyrus, as measured by Dnmt3a immunoreactivity, as well as serotonin metabolism. No further changes in synaptophysin, PSD-95, or Dnmt3a immunoreactivity were seen in the cortical or hippocampal areas investigated. These findings show that gestational stress and SSRI medication affect the neurobiology of the maternal brain in a region-specific manner. This work adds to a much needed area of research aimed at understanding neurobiological changes associated with maternal depression and the role of SSRI treatment in altering these changes in the female brain.</style></abstract><accession-num><style face="normal" font="default" size="100%">27060483</style></accession-num><notes><style face="normal" font="default" size="100%">10.1016/j.neuroscience.2016.03.068</style></notes><auth-address><style face="normal" font="default" size="100%">Department of Biological Sciences, Ohio University, Athens, OH, USA.Department of Neuroscience, Maastricht University, Netherlands.Department of Pharmacology, Medical School, University of Athens, Greece.Department of Biological Sciences, Ohio University, Athens, OH, USA; Department of Neuroscience, Maastricht University, Netherlands; IRSET INSERM UMR1085, University of Rennes 1, France. Electronic address: j.pawluski@gmail.com.</style></auth-address><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record></records></xml>